PROTACs: A novel strategy for cancer therapy

Liu, Jing, Ma, Jia, Liu, Yi, Xia, Jun, Li, Yuyun, Wang, Z. Peter, Wei, Wenyi·2020·Seminars in Cancer Biology
DOI 10.1016/j.semcancer.2020.02.006

Cited by (193)

Items 101–193 of 193

  1. PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
    André T. S. Vicente, Jorge A. R. Salvador · 2024 · MedComm
  2. Mapping intratumor heterogeneity across layers for advancing immunotherapy
    Jean‐Christophe Marine, Osnat Bartok, Shira Sagie, Pietro Paolo Vitiello, Alberto Bardelli, Chen Weller, Tiangen Chang, Claudia Tonelli, Stefani Spranger, Eytan Ruppin et al. · 2026 · Cell
  3. Precise Modulation of Protein Degradation by Smart PROTACs
    Junfei Cheng, Guoqiang Dong, Wei Wang, Chunquan Sheng · 2024 · ChemBioChem
  4. A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-κB1 p105 to p50: A potential for a tumor-suppressive PROTAC
    Gilad Goldhirsh, Yelena Kravtsova‐Ivantsiv, Satish Gandhesiri, Tamar Ziv, Ashraf Brik, Aaron J. Ciechanover · 2021 · Proceedings of the National Academy of Sciences
  5. Small-Molecule Degraders of Cyclin-Dependent Kinase Protein: A Review
    Bin Yu, Zekun Du, Yuming Zhang, Zhiyu Li, Jinlei Bian · 2021 · Future Medicinal Chemistry
  6. PROTACs: The Future of Leukemia Therapeutics
    Zubair Anwar, Muhammad Shahzad Ali, Antonio Galvano, Alessandro Perez, Maria La Mantia, Ihtisham Bukhari, Bartłomiej Świątczak · 2022 · Frontiers in Cell and Developmental Biology
  7. The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins
    Mingyue Mou, Wei‐Cheng Yang, Guangyi Huang, Xiaoyan Yang, Xiao Li Zhang, Wishwajith Kandegama, Charles R. Ashby, Ge‐Fei Hao, Yangyang Gao · 2025 · Medicinal Research Reviews
  8. Innovating Cancer Treatment Through Cell Cycle, Telomerase, Angiogenesis, and Metastasis
    Tooba Yousefi, Bahareh Mohammadi Jobani, Reyhaneh Taebi, Durdi Qujeq · 2024 · DNA and Cell Biology
  9. Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
    Li Liu, Lihong Shi, Zhaodi Wang, Jun Zeng, Yue Wang, Hongtao Xiao, Yongxia Zhu · 2022 · Frontiers in Endocrinology
  10. Deciphering roles of TRIMs as promising targets in hepatocellular carcinoma: current advances and future directions
    Jie Zhang, Yuting Zhou, Jiao Feng, Xuanfu Xu, Jianye Wu, Chuanyong Guo · 2023 · Biomedicine & Pharmacotherapy
  11. JAC4 Inhibits EGFR-Driven Lung Adenocarcinoma Growth and Metastasis through CTBP1-Mediated JWA/AMPK/NEDD4L/EGFR Axis
    Kun Ding, Xuqian Jiang, Zhangding Wang, Lu Zou, Jiahua Cui, Xiong Li, Chuanjun Shu, Aiping Li, Jianwei Zhou · 2023 · International Journal of Molecular Sciences
  12. Targeting PD-1 post-translational modifications for improving cancer immunotherapy
    Jie Shi, Chuan He, Li Chen, Xixin Xing, Wenyi Wei, Jinfang Zhang · 2025 · Cell Insight
  13. Design and development of PROTACs: A new paradigm in anticancer drug discovery
    Vishal Mathur, Mukund Jha, Iqra Zai, Moksh Mahajan, Shagufi Nazar, Shaheen Ali, Anam Ilyas, Sana Tanweer, Javed Ali, Ozair Alam · 2025 · Medicine in Drug Discovery
  14. PROTACs: Novel approach for cancer breakdown by breaking proteins
    Humera Memon, Bhoomika M. Patel · 2022 · Life Sciences
  15. PROTAC as a novel anti-cancer strategy by targeting aging-related signaling
    Yunhua Peng, Donghua Liu, Daoyuan Huang, Hiroyuki Inuzuka, Jing Liu · 2024 · Seminars in Cancer Biology
  16. Recent Advances in enhancer of zeste homolog 2 Inhibitors: Structural insights and therapeutic applications
    Ruolin Cao, Jiayang Ni, Xiaoyu Zhang, Minggang Qi, Zhen Zhang, Zhongbo Liu, Guoliang Chen · 2024 · Bioorganic Chemistry
  17. Recent Advancements in the Discovery of Cereblon-Based Protease-Targeted Chimeras With Potential for Therapeutic Intervention
    Harbinder Singh, Devendra K. Agrawal · 2022 · Future Medicinal Chemistry
  18. The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy
    Xuemei Wang, Ying Zhang, Yao Wu, Hongjing Cheng, Xueju Wang · 2023 · Frontiers in Immunology
  19. Functionally analyzing the important roles of hepatocyte nuclear factor 3 (FoxA) in tumorigenesis
    Bing Xin Gao, Wei Xie, Xueji Wu, Lei Wang, Jianping Guo · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  20. An updated review on the role of small molecules in mediating protein degradation
    Zumei Wu, Yulong Li, Jinyun Dong, Jiang‐Jiang Qin · 2025 · European Journal of Medicinal Chemistry
  21. Targeted degradation of DDR1 by proteolytic targeting chimera reverses immune exclusion for tumor immunotherapy
    Xiaoyu Wang, Zeng Ju, Shilin Liu, Fei Qi, Chao Xin, Xinyu Li, Yan Ping Gao, Fan Dan, Yuxuan Qu, Zhiyi Ren et al. · 2025 · European Journal of Medicinal Chemistry
  22. AKIP1 accelerates glioblastoma progression through stabilizing EGFR expression
    Sicheng Wan, Chaolong Liu, Chongyang Li, Zhi Wang, Gaichao Zhao, Jingui Li, Wenhao Ran, Xi Zoë Zhong, Yongsen Li, Li Zhang et al. · 2023 · Oncogene
  23. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
    Xuanrong Chen, Shen Haishan, Yi Shao, Qianwang Ma, Yuanjie Niu, Zhiqun Shang · 2021 · Translational Andrology and Urology
  24. Proteolysis-Targeting Chimera Molecules Targeting SHP2
    Dandan Yu, Mengzhu Zheng, Yang Liu, Lixia Chen, Hua Li · 2022 · Future Medicinal Chemistry
  25. Nano-TPD: Using nanoparticle-based systems to improve the delivery and therapeutic effect of targeted protein degraders
    Kuntala Dey, Nina Erwin, Nicolas Molina, Hui Chen, Mei He, Guangrong Zheng · 2025 · Medicinal Chemistry Research
  26. The Activity of Novel BCR-ABL Small-Molecule Degraders Containing Pyrimidine Rings and Their Role in Overcoming Drug Resistance
    Xu Zhang, Linglan Tu, Haohuan Chai, Zilin Li, Yuhan Fu, Xiaoliang Zheng, Shenxin Zeng, Liyan Cheng · 2022 · Journal of Oncology
  27. An updated review of small-molecule HPK1 kinase inhibitors (2016-present)
    Yiping Duan, Zhichao Guo, Wenyi Zhong, Jichao Chen, Shengtao Xu, Jie Liu, Jinyi Xu · 2024 · Future Medicinal Chemistry
  28. PROTAC technology for prostate cancer treatment
    Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei · 2025 · Acta Materia Medica
  29. Chimeric peptide-engineered photodynamic PD-L1 degrader for activating colorectal cancer immunity in combination with exosomal PD-L1 inhibition
    Yuxuan Wei, Zuxiao Chen, Wenfeng Zhu, Rongrong Zheng, Chu‐Yu Huang, Ni Yang, Jing Wen, Dawei Zhang, Hong Bo Cheng, Shiying Li · 2025 · Science China Materials
  30. Acetyl-CoA Carboxylase Proteolysis-Targeting Chimeras: Conceptual Design and Application as Insecticides
    Qi Keng Xu, Hao Feng, Zhong Li, Xusheng Shao · 2024 · Journal of Agricultural and Food Chemistry
  31. Circular RNAs With Efficacy in PreclinicalIn VitroandIn VivoModels of Esophageal Squamous Cell Carcinoma
    Ulrich H. Weidle, Tatjana Sela, Ulrich Brinkmann, Jens Niewoehner · 2022 · Cancer Genomics & Proteomics
  32. Proteolysis-Targeting Chimeras in Breast Cancer Therapy
    Jifa Zhang, Liang Ouyang · 2020 · Future Medicinal Chemistry
  33. Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy
    Kunjian Lei, Jingying Li, Zewei Tu, Chuandong Gong, Junzhe Liu, Min Hua Luo, Wenqian Ai, Lei Wu, Yishuang Li, Zhihong Zhou et al. · 2024 · Theranostics
  34. Dysregulation of ubiquitination modification in renal cell carcinoma
    Hongjie You, Hui Zhang, Xiaofeng Jin, Zejun Yan · 2024 · Frontiers in Genetics
  35. PROTACs: A Hope for Breast Cancer Patients?
    Rajwinder Kaur, Gaurav Chaudhary, Amritpal Kaur, Pargat Singh, Gagan Deep Longowal, Gayatri P. Sapkale, Sandeep Arora · 2021 · Anti-Cancer Agents in Medicinal Chemistry
  36. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules
    Muhammad Zafar Irshad Khan, Adila Nazli, Youlu Pan, Jian‐Zhong Chen · 2022 · Current Medicinal Chemistry
  37. Cell‐Targeting Bio‐Catalytic Killer Protocell for High‐Order Assembly Guided Cancer Cell Inhibition
    Shuhan Xiong, Zeqi Huang, Vincent Mukwaya, Weili Zhao, Li Wang, Hongjing Dou · 2025 · Small
  38. Advances in light-controllable PROTACs: Design strategies, therapeutic applications and current challenges
    Ji Wu, Ziyue Wang, Shi-Xuan Tan, Tingyu Li, Bingbing Chen, Qiqi Chen, Hao Li, Jin-Bo Niu, Xiang-Jing Fu, Jian Song et al. · 2025 · Bioorganic Chemistry
  39. Opportunities and challenges of PROTAC in the treatment of protein-driven diseases
    Zhe Zhou, Peng Liu, Yang Li, Xuelian Liu, Jinyao Li · 2026 · Results in Chemistry
  40. Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradation
    Ni‐Yuan Zhang, Jian-Xiao Liang, Bei-Ning Hu, Yi Wang, Hong‐Wei An, Hao Wang · 2026 · Advanced Drug Delivery Reviews
  41. The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions
    Carmelo Laface, Francesco Giuliani, Assunta Melaccio, Maria Nicla Pappagallo, Anna Natalizia Santoro, Martina Perrone, Pierluigi De Santis, Chiara Guarini, Daniela Carrozzo, Palma Fedele · 2023 · Journal of Clinical Medicine
  42. Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges
    Yuxuan Wang, Yanyi He, Qidong You, Lei Wang · 2024 · Drug Discovery Today
  43. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review
    André T. S. Vicente, Jorge A. R. Salvador · 2023 · Expert Opinion on Therapeutic Patents
  44. Unraveling role of ubiquitination in drug resistance of gynecological cancer
    Li Yu · 2024 · American Journal of Cancer Research
  45. Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics
    Jinglin Tang, Han Liu, Jinze Li, Yibo Zhang, Suyang Yao, Kan Yang, Zhi‐Hao You, Xiaoqiang Qiao, Yali Song · 2024 · Future Medicinal Chemistry
  46. The PROTAC selectively degrading BCL-XL inhibits the growth of tumors and significantly synergizes with Paclitaxel
    Fenglan Qiu, Yachuan Tao, Yue Chen, Zhuqin Shen, Xuan Huang, Wenfu Tan, Taomin Huang, Xin Cao · 2024 · Biochemical Pharmacology
  47. Precision targeting of ALK-positive lung cancer: Engineering HFN@MS4078 nanocages for optimized PROTAC delivery
    Yuan Fan, Yuxiang Liu, Liujiao Wang, Huashan Xu, Lele Yu, Yue Lang, Huafei Li, Fu‐Xue Chen, Shini Feng · 2025 · Colloids and Surfaces B Biointerfaces
  48. Targeted protein degradation: species, diseases and efficient utilization
    Tian Yue, Jian He, Jun Hou · 2025 · Journal of Translational Medicine
  49. Exosome-mediated intercellular communication and PROTACs delivery: A dual approach for precision therapy in colon cancer
    Popat B Mohite, Abhijeet Vishnu Puri, Shubham V. Munde, Vaishnavi Yadav, Nobendu Mukerjee, Riteshkumar Patil, Nihar Mahindrakar, G. V. Siva Prasad, Rajni Verma, Aashna Sinha · 2024 · Journal of Drug Delivery Science and Technology
  50. PROTACs improve selectivity for targeted proteins
    Lihua Liu, Xian Guan, Jiezhen Zhuo, Xifeng Wu, Xin Han · 2025 · Acta Materia Medica
  51. Predicting PROTAC off-target effects via warhead involvement levels in drug–target interactions using graph attention neural networks
    Yutong Hu, Kieran Didi, Adam P. Cribbs, Jianfeng Sun · 2025 · Computational and Structural Biotechnology Journal
  52. Advances in light-activated PROTACs and phototherapy-combined approaches for cancer treatment
    Wei Zhang, Shuai Li, Hong Yuan, Jingyuan Zhao · 2025 · European Journal of Medicinal Chemistry
  53. Spatiotemporally controlled ferritin-targeting PROTAC nanoplatform for visualized manipulation of endogenous “Iron pool” in pancreatic cancer therapy
    Xiaoyan Yang, Wangping Luo, Yining Wang, Yuanfei Lu, Jieni Yu, Chengjia Liu, Weilin Wang, Yongzhong Du, Ri‐Sheng Yu · 2025 · Materials Today Bio
  54. Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
    Lin Ma, Xin Han · 2024 · Elsevier eBooks
  55. Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
    Xing Yi Yan, Yuan Yuan Kang, Ze Yan Zhang, Ping Cheong Huang, Chang Yang, Hua Naranmandura · 2024 · Expert Opinion on Therapeutic Targets
  56. Extracellular vesicle-based targeted protein degradation platform for multiple extracellular proteins
    Bide Tong, Xiaoguang Zhang, Dingchao Zhu, Yulei Wang, Junyu Wei, ZiXuan Ou, Huaizhen Liang, Hanpeng Xu, Zhengdong Zhang, Jie Lei et al. · 2026 · EMBO Molecular Medicine
  57. SonoPIN enables precise, noninvasive, and efficient intracellular delivery of PROTACs
    Yuqi Wu, Mingyuan Liu, Ke Li, S. Li, Lai Yee Phoon, John Mai, Ying Chen, Wei Yan, Shu Nakajima Lan, Joseph Rufo et al. · 2026 · Proceedings of the National Academy of Sciences
  58. Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy
    Jiayi Song, Xu Wei, Kai He, Ruixin Ge, Mengxuan Li, Tinghui Bai, Han Han, Caiyun You, Mengyu Liao, Wei Pan et al. · 2026 · Signal Transduction and Targeted Therapy
  59. Special issue: Targeting E3 ubiquitin ligases for cancer therapy
    Zhiwei Peter Wang, Wenyi Wei · 2020 · Seminars in Cancer Biology
  60. The First‐In‐Class Deubiquitinase‐Targeting Chimera Stabilizes and Activates cGAS
    Zhijie Deng, Li Chen, Chao Qian, Jing Liu, Qiong Di Wu, Xiangyang Song, Yan Xiong, Zhen Wang, Xiaoping Hu, Hiroyuki Inuzuka et al. · 2024 · Angewandte Chemie
  61. Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
    Jing Yang, Qing Qiao, Na Lin, Miaomiao Niu, Lin Su, Boshu Yin · 2025 · Journal of Biochemical and Molecular Toxicology
  62. Benchmarking Deep Learning for PROTAC Ternary Complex Prediction
    Haoyu Chen, Fengjiao Wei, Jiajie Li, Zhuobin Shi, S L Chen, Yu -Chun Fang, Shuxin Li, Xinru Gao, Lin Ju, Senbiao Fang et al. · 2026 · Proteins Structure Function and Bioinformatics
  63. Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
    Shaik Abdul Rahaman, Garla Venkateswarlu, Sakshi Patel, Prem Shankar Mishra, Rahul Kumar, Nayyar Parvez · 2026 · Current Topics in Medicinal Chemistry
  64. Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report
    Ruiyue Wu, Xi Chen, Tong Li, Y X Zhang, Xiaoling Ling · 2026 · Frontiers in Oncology
  65. Precision‐Engineered PROTACs: Integrating Physical and Chemical Strategies for Targeted Cancer Therapy
    Hong Yao, Yujing Zhang, Hongyun Zhao, Meng Liu, Chang Liu, Pengyun Wang, Wujun Chen, Zhu Guo, Dongming Xing, Jinghua Yang et al. · 2026 · Small
  66. OTX015 PROTACs: Emerging Novel Therapeutic Agents in Cancer Treatment
    Rajwinder Kaur, Pargat Singh, Amritpal Kaur, Gaurav Chaudhary, Diksha Choudhary, Paranjeet Kaur, Sanjeev Kumar Sahu · 2024 · BIO Web of Conferences
  67. WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
    Muhammad Zafar Irshad Khan, Adila Nazli, Iffat Naz, Dildar Khan, Ihsan‐ul Haq, Jianzhong Chen · 2023 · Journal of Pharmaceutical Analysis · Retracted
  68. Unlocking Cellular Control: The Promise of PROTACs in Disease Intervention
    Aishani Kumar, Thendral Yalini, Sunil Kumar C · 2024 · Science Reviews Biology
  69. Corrigendum to “Modeling PROTAC degradation activity with machine learning” [Artif. Intell. Life Sci. 6 (2024) 100104]
    Stefano Ribes, Eva Nittinger, Christian Tyrchan, Rocío Mercado · 2024 · Artificial Intelligence in the Life Sciences
  70. Clinical Development of PROTACs
    Advait Dubey, Kavita Pal, Vikram Gota · 2024 · Springer eBooks
  71. Hypoxia-activated prodrugs
    Wagdy Mohamed Eldehna · 2024 · Elsevier eBooks
  72. A novel antitumor therapy: degradation of c-SRC by PROTAC
    Xing YANG, Yanyan Ji, Wang Li, JingChao YANG, Nan Li, Shengjia Tian, Jiayi Li, HaiTao CHEN, FengTang YANG, Yuzhong Cui et al. · 2025 · Scientia Sinica Vitae
  73. A patent review of MLKL modulators (2023 – present)
    Bowen Wan, Cheng‐Shi Jiang, Chunlin Zhuang · 2025 · Expert Opinion on Therapeutic Patents
  74. PROTACS- targeted protein degradation as a path to precision cancer therapeutics
    Hannah R Gatley, Paul B. Fisher, Swadesh Kumar Das · 2025 · Advances in cancer research
  75. Analogues et outils moléculaires de composés naturels ciblant la protéine OSBP : synthèse et validation biologique
    Carole Guimard · 2023 · theses.fr (ABES)
  76. Rational design, molecular characterization and dissociation mechanisms of PROTACs targeting hFAAH
    Yuxin Xiao, Na Li, Dazhi Cheng, Yan Cheng, Huaichuan Duan, Yuting Song, Xinmin Wang, Zuoxin Ou, Ting Luo, Hubing Shi et al. · 2026 · Physical Chemistry Chemical Physics
  77. Progress of structurally diverse cereblon (CRBN) ligands and their application in PROTAC degraders
    Shuguang Yang, Yanxin Zhang, Xiaoping Song, Qingchao Liu, Daidi Fan, Ying Xu · 2026 · Bioorganic Chemistry
  78. HSP70: From molecular chaperone to integrative hub in castration-resistant prostate cancer therapeutic resistance
    Qiuyu Liu, Tianwen Huang, Lu Li, Zhongxiu Liang, Liu Y, Jian Xiao, Xueni Wang · 2026 · European Journal of Pharmacology
  79. Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation
    Lili Jiang, Wenyan Yang, Yanqing Liu, Gangjian Li, Xiaomin Luo, Yubo Zhou, Jiangjiang Qin, Youlu Pan, Wenhai Huang · 2026 · European Journal of Pharmaceutical Sciences
  80. L013 promotes NRF2 degradation in NRFA-subtype esophageal squamous cell carcinoma
    Xiao Yu, Yue Wu, Xiuyun Sun, Rui Han, Yi Cai, Wei Zeng, Yang Li, Yuhao Wang, Yahui Zhao, Yu Rao et al. · 2026 · Cell Reports Medicine
  81. Aptamer-ROTAC assembled DNA nanocentipede for specific targeting of HSPA8 in hepatocellular carcinoma therapy
    Xiaoke Wu, Yugang Xiao, Zhirui Song, Hongbo Zhang, Li Yin, Nannan Fang, Qubo Zhu · 2026 · Chemical Engineering Journal
  82. Protein degraders targeting JAK/STAT3 signaling pathway are emerging therapeutic modalities for human cancers
    Xinyu Feng, Nanjing Li, Xiaorong Chen, Xinyue Cao, Jingling Dai, Shaoquan Xiong, Zhu Yuan · 2026 · Biochemical Pharmacology
  83. In Situ Monitoring PROTAC Molecule-Induced Target Protein Degradation Process in Living Cells by Multi-channel Fluorescence Cross-Correlation Spectroscopy
    Chaoliang Diao, Ziyang Zhao, Xinwei Lu, Kun Zang, Yi Dong, Chaoqing Dong, Jicun Ren · 2026 · Analytical Chemistry
  84. BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
    BindingDB · 2024 · UC San Diego
  85. BindingDB Entry 50021665: The application of PROTAC in HDAC.
    BindingDB · 2025 · UC San Diego
  86. BindingDB Entry 50006137: Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.
    BindingDB · 2024 · UC San Diego
  87. BindingDB Entry 50017830: Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
    BindingDB · 2023 · UC San Diego
  88. BindingDB Entry 50017484: Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT.
    BindingDB · 2023 · UC San Diego
  89. BindingDB Entry 50015587: A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    BindingDB · 2023 · UC San Diego
  90. BindingDB Entry 50016127: Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
    BindingDB · 2023 · UC San Diego
  91. BindingDB Entry 50018778: Targeting PGAM1 in cancer: An emerging therapeutic opportunity.
    BindingDB · 2024 · UC San Diego
  92. BindingDB Entry 50022804: Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.
    BindingDB · 2026 · UC San Diego
  93. BindingDB Entry 50021132: Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    BindingDB · 2025 · UC San Diego